Philips Healthcare presented MyoStrain® at the annual Radiology Society of North America (RSNA) 2020 virtual event and discussed how MyoStrain's MRI-based cardiac diagnostic solutions may help transform cardiovascular care and enable physicians to quantify subtle changes in intra-myocardial heart function.
The full presentation from Philips at RSNA is available here.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.